Grasl-Kraupp B, Ruttkay-Nedecky B, Müllauer L, Taper H, Huber W, Bursch W, Schulte-Hermann R
Institut für Tumurbiologie-Krebsforschunng der Universität Wien, Austria.
Hepatology. 1997 Apr;25(4):906-12. doi: 10.1002/hep.510250420.
We quantitatively assessed rates of cell replication and of apoptosis during the development and regression of liver cancer. In rats, apoptotic activity gradually increased from normal liver to putative preneoplastic foci (PPF), to hepatocellular adenoma (HCA), and to hepatocellular carcinoma (HCC). At all stages, rates of cell replication were higher than of apoptosis, allowing a preferential net gain of (pre)neoplastic cells. As in rats, in human HCC, birth and death rates were increased manifold, indicating a species-independent phenomenon. Implications of the increasing cell turnover were studied in rats using the administration and withdrawal of nafenopin (NAF), a liver mitogen and nongenotoxic carcinogen. Prolonged NAF treatment enhanced cell number in normal liver by 25%, while PPF and liver tumors were amplified at least 100-fold. After stopping NAF treatment, cell replication ceased, while cell elimination by apoptosis was increased in normal and (pre)neoplastic liver. HCA and HCC showed the most pronounced shifts from replication toward apoptosis. As a result, 5 weeks after halting NAF, 20% of cells in normal liver, but about 85% of (pre)neoplastic lesions including HCC, were eliminated. The implications of these findings include that nongenotoxic carcinogens can act as survival factors even for malignant cells. Furthermore, tumor cells not only exhibit excessive proliferation, but also undergo apoptosis at rates that far exceed those in normal tissue. Therefore, inhibition of cell death by the survival activity of nongenotoxic carcinogens results in selective growth of (pre)neoplastic lesions. On the other hand, blockade of survival effects leads to excessive apoptosis in (pre)neoplasia and seems promising as a therapeutic concept for the selective elimination of (liver) cancer.
我们定量评估了肝癌发生发展及消退过程中的细胞复制率和凋亡率。在大鼠中,凋亡活性从正常肝脏逐渐增加到假定的癌前病灶(PPF)、肝细胞腺瘤(HCA),再到肝细胞癌(HCC)。在所有阶段,细胞复制率均高于凋亡率,使得(癌前)肿瘤细胞有优先的净增加。与大鼠一样,在人类肝癌中,细胞出生率和死亡率均大幅增加,表明这是一种不依赖物种的现象。我们通过给予和撤掉萘夫平(NAF)(一种肝脏促有丝分裂剂和非基因毒性致癌物)来研究大鼠中细胞更新增加的影响。长期给予NAF治疗使正常肝脏中的细胞数量增加了25%,而PPF和肝脏肿瘤至少扩增了100倍。停止NAF治疗后,细胞复制停止,而正常肝脏和(癌前)肿瘤肝脏中通过凋亡进行的细胞清除增加。HCA和HCC表现出从复制向凋亡最明显的转变。结果,在停止NAF治疗5周后,正常肝脏中20%的细胞被清除,但包括HCC在内的约85%的(癌前)肿瘤病变被清除。这些发现的意义包括,非基因毒性致癌物甚至可以作为恶性细胞的生存因子。此外,肿瘤细胞不仅表现出过度增殖,而且其凋亡率远远超过正常组织。因此,非基因毒性致癌物的生存活性对细胞死亡的抑制导致了(癌前)肿瘤病变的选择性生长。另一方面,可以阻断生存效应导致(癌前)肿瘤过度凋亡,这似乎是一种有前景的选择性消除(肝脏)癌的治疗理念。